Skip to main content

Table 3 Comparison between patients with and without pseudolithiasis

From: Ceftriaxone-associated pseudolithiasis in hemodialysis patients: a case series study

  Pseudolithiasis (n = 10) No pseudolithiasis (n = 11) P value
Age (years) 73.9 ± 16.5 71.1 ± 18.7 0.72
Male sex, n (%) 6 (63.6) 7 (61.9) 0.86
DM, n (%) 5 (50.0) 2 (18.2) 0.12
CVD, n (%) 5 (50.0) 4 (36.4) 0.53
Body mass (kg) 50.1 ± 12.5 52.4 ± 9.0 0.64
Body mass index (kg/m2) 19.9 ± 4.3 20.9 ± 2.8 0.53
Ca-containing drug, n (%) 2 (20.0) 3 (27.3) 0.70
Bed-bound, n (%) 6 (60.0) 4 (36.4) 0.28
Fasting, n (%) 0 (0) 1 (15.4) 0.33
Laboratory
 Albumin (g/dL) 2.8 ± 0.8 3.0 ± 0.6 0.35
 Calcium (mg/dL) 9.5 ± 0.6 9.4 ± 0.6 0.75
 Int-PTH (pg/mL) 113.0 (81.0–163.0) 143.0 (94.0–228.0) 0.61
Dose of CTRX (mg/kg/day) 21.3 (18.1–22.4) 17.2 (16.1–19.8) 0.17
Duration of CTRX infusion (day) 12 (8.3–14) 4 (2–8) 0.00872*
Total dose of CTRX (g) 12.5 (9.3–14) 4 (2–8) 0.00476*
  1. DM Diabetes mellitus, CVD Cerebrovascular disease, Ca Calcium, Int-PTH Intact parathormone, CTRX Ceftriaxone
  2. *Statistically significant (P < 0.05)
\